...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: BET Inhibitors may help Overcome a Newly Recognized Form of Resistance to Prostate Cancer Drugs

Great finds masila. Thanks for posting.

From the first study it appears they are getting close to identifying a patient population that may be an ideal target for zen3694. If the research is successful there may be an identifiable market for the drug clinically.

Very exciting.

Toinv

Share
New Message
Please login to post a reply